NCT02252263: Phase 1: Elotuzumab (BMS-901608) With Lirilumab (BMS-986015) or Urelumab (BMS-663513)
- Completed
- Dec 3, 2014
- 1 min read
NCT02252263: Phase 1: A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
To assess the safety and tolerability, characterize the dose limiting toxicities (DLTs) and identify the maximally tolerated dose (MTD) of Elotuzumab administered in combination with either Lirilumab or Urelumab in subjects with multiple myeloma.
Sponsor
Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT02252263
Official Title: A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
First Posted : September 30, 2014
Click here for details on ClinicalTrials.gov
Elotuzumab (Code C66982)
BMS-901608
Elotuzumab
ELOTUZUMAB
Empliciti
HuLuc-63
HuLuc63
PDL-063
PDL063
anti-CS1 monoclonal antibody HuLuc63
Lirilumab (Code C103820)
BMS-986015
IPH2102
Lirilumab
LIRILUMAB
anti-KIR monoclonal antibody IPH2102
Urelumab (Code C62449)
BMS-663513
Immunoglobulin G4, Anti-(Human Receptor 4-1BB) (Human Gamma-Chain), Disulfide with Human Kappa-Chain, Dimer
Urelumab
URELUMAB
anti-4-1BB monoclonal antibody
anti-CD137 monoclonal antibody
Drug: Elotuzumab
Drug: Lirilumab
Drug: Urelumab
Location
United States, Arkansas
United States, Maryland
United States, New York
United States, Ohio
United States, Oregon
United States, Pennsylvania
Europe
Spain